Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering
Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering
PONTE VEDRA, Fla., Jan. 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the closing of its initial public offering of 1,400,000 shares of common stock at a public offering price of $5.00 per share for gross proceeds of $7,000,000, before deducting underwriting discounts and estimated offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 210,000 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount.
蓬特韦德拉 (佛罗里拉省), 2023 年一月二十四日 /通社/-- 腎臟治療有限公司（納斯達克：CVKD）一家專注於開發具有孤兒藥物指示的臨床階段新型心腎治療 tecarfarin 的生物製藥公司，今天宣布以公開發行價格公開發行 1,400,000 股普通股的首次公開發行 5.00 美元 每股總收益 七百萬元，扣除承保折扣和預估提供費用之前。此外，本公司已授予承銷商一個 45 天的選擇權，可以額外購買最多 210,000 股普通股，以支付以首次公開發售價（扣除承銷折扣）的超額配股。
The Company's common stock began trading on the Nasdaq Capital Market on January 20, 2023, under the symbol "CVKD."
該公司的普通股於日期在納斯達克資本市場開始交易 2023年1月20日，下面的符號「CVKD。」
Boustead Securities, LLC acted as lead underwriter for the offering.
寶斯特證券有限責任公司擔任該項發售的主要承銷商。
A registration statement on Form S-1 (File No. 333-267562) relating to these shares was filed with the Securities and Exchange Commission ("SEC") and was declared effective on January 19, 2023. The offering was made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from Boustead Securities, LLC, via email at [email protected] or by calling +1 (949) 502-4408 or standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 395, Irvine, CA 92618, USA. In addition, a copy of the final prospectus relating to the offering may be obtained via the SEC's website at www.sec.gov.
有關這些股份的 S-1 表格（檔案編號 333-267562）的登記聲明已向美國證券交易委員會（「美國證券交易委員會」）提交，並於日期宣佈生效 2023年1月19 日。此次發行僅通過招股說明書提出。與發行相關的最終招股說明書的副本可以從博斯特證券有限責任公司獲得，通過電子郵件至 [電子郵件保護] 或致電 +1（949）502-4408 或在寶斯特證券有限責任公司，收件人：股權資本市場，6 風險，套房 395， 欧文 (加利福尼亚州 92618, 美國。此外，與發行有關的最終招股章程副本，可透過 SEC 的網站（www.sec.gov）索取。
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
本新聞稿並不構成要約出售或徵求購買這些證券的要約，也不會在任何該等州或司法管轄區的證券法根據任何該等州或司法管轄區的證券法進行註冊或資格前違法的任何國家或司法管轄區出售該等證券。
ABOUT CADRENAL THERAPEUTICS, INC.
關於腎上腺治療, 公司.
Cadrenal Therapeutics is focused on developing tecarfarin, a novel cardiorenal therapy with orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to target a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin has been evaluated in eleven human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2 and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: .
腎臟治療專注於開發 tecarfarin，這是一種新穎的心腎療法，用於預防末期腎臟疾病或 ESRD 患者的全身性血栓栓塞（血栓）或 ESRD 患者的全身血栓栓塞（血栓）或心房顫動（不規則心跳）或 AFIB。替卡法林是一種維生素 K 拮抗劑口服抗凝劑，旨在針對與治療血栓形成和 AFIB 中最常用的處方藥物不同的途徑。他卡法林已經在十一項人體臨床試驗和 1,000 多個人中進行了評估。在 1 期，2 期和 2/3 期臨床試驗中，替卡法林通常在健康的成年受試者和慢性腎臟疾病患者中都具有良好的耐受性。欲了解更多信息，請訪問：。
Safe Harbor Statement
安全港聲明
Any statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the "Risk Factors" section of the initial public offering prospectus filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Cadrenal Therapeutics specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
本新聞稿中包含有關未來預期、計劃和前景的任何聲明，以及任何其他有關非歷史事實的事項的聲明，都可能構成「前瞻性陳述」。「預料」，「相信」，「繼續」，「可能」，「估計」，「期望」，「意圖」，「可能」，「計劃」，「潛力」，「預測」，「項目」，「應」，「目標」，「意志」和類似的表達式旨在識別前瞻性語句，儘管不是所有前瞻性語句都包含這些前瞻性語句。由於各種重要因素，包括向 SEC 提交的首次公開發行招股章程中「風險因素」一節中討論的因素，實際結果可能與該等前瞻性陳述有重大不同。本新聞稿中包含的任何前瞻性聲明僅在本文日期發言，除了聯邦證券法要求外，Cad肾 Therapretics 特別不承擔任何更新前瞻性聲明的義務，無論是由於新信息，未來事件還是其他原因。
For more information, please contact:
欲了解更多信息，請聯繫：
For Underwriter Inquiries:
Boustead Securities, LLC
Keith Moore, CEO
949-502-4408
[email protected]
對於承銷商查詢：
寶德證券有限責任公司
基斯·摩尔首席執行官
949-502-4408
[電子郵件保護]
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
[email protected]
腎上腺治療：
马修·施特, 首席財務官
858-337-0766
[電子郵件保護]
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700,
[email protected]
投資者：
萊瑟姆合作夥伴有限公司
罗伯特·布鲁姆, 管理合夥人
602-889-9700,
[電子郵件保護]
SOURCE Cadrenal Therapeutics, Inc.
來源腎腎上腺治療, 公司.
譯文內容由第三人軟體翻譯。